Dr. Princy Kumar
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 46
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 166
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
DC license 17469
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Georgetown University Hospital Washington, DC
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 166
- Services billed
- 433
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 106 | 43 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 95 | 41 |
| Established patient office or other outpatient visit, 40-54 minutes | 67 | 47 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 38 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Descovy (emtricitabine/tenofov alafenam) | 50 |
| Tivicay (dolutegravir sodium) | 48 |
| Juluca (dolutegravir/rilpivirine) | 39 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 35 |
| Prezcobix (darunavir/cobicistat) | 21 |
| Atorvastatin Calcium Other prescribers in Washington, DC | 19 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 17 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Washington, DC | 16 |
| Lisinopril Other prescribers in Washington, DC | 15 |
| Allopurinol Other prescribers in Washington, DC | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 38 payments worth $27,877 in total to this clinician.
| Merck Sharp & Dohme LLC | $19,108 |
|---|---|
| Gilead Sciences, Inc. | $8,769 |
| Consulting Fee | $23,380 |
|---|---|
| Travel and Lodging | $3,562 |
| Food and Beverage | $934 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Oct 13, 2025 | Consulting Fee | $9,280 |
| Gilead Sciences, Inc. Dec 8, 2025 | Consulting Fee Sunlenca · HIV Company’s description;4288242;GTF;10048275 | $5,950 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee | $5,800 |
| Gilead Sciences, Inc. Jun 24, 2025 | Consulting FeeCompany’s description;4047071;SAP;10048275 | $1,350 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $1,000 |
| Merck Sharp & Dohme LLC Aug 5, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $591 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288161;GTF;10048275 | $397 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288135;GTF;10048275 | $313 |
| Merck Sharp & Dohme LLC Aug 6, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $313 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $275 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 8, 2025 | Consulting Fee Sunlenca · HIV Company’s description;4288242;GTF;10048275 | $5,950 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288135;GTF;10048275 | $313 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288198;GTF;10048275 | $58.31 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA Company’s description;4288206;GTF;10048275 | $58.00 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288161;GTF;10048275 | $397 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA · in-kind Company’s description;4288194;GTF;10048275 | $160 |
| Gilead Sciences, Inc. Nov 13, 2025 | Travel and Lodging Sunlenca · HIV · travel to Boston, MA Company’s description;4288156;GTF;10048275 | $27.52 |
| Merck Sharp & Dohme LLC Oct 13, 2025 | Consulting Fee | $9,280 |
| Merck Sharp & Dohme LLC Oct 13, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Sep 29, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $260 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $275 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $260 |
| Merck Sharp & Dohme LLC Sep 28, 2025 | Travel and Lodging INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $140 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee | $5,800 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Travel and Lodging travel to Philadelphia, PA | $150 |
| Merck Sharp & Dohme LLC Aug 6, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $313 |
| Merck Sharp & Dohme LLC Aug 6, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $248 |
| Merck Sharp & Dohme LLC Aug 5, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $591 |
| Merck Sharp & Dohme LLC Aug 5, 2025 | Travel and Lodging DELSTRIGO · INFECTIOUS DISEASE · travel to Philadelphia, PA · in-kind | $162 |
| Gilead Sciences, Inc. Jun 24, 2025 | Consulting FeeCompany’s description;4047071;SAP;10048275 | $1,350 |
| Merck Sharp & Dohme LLC Jan 22, 2025 | Consulting Fee INFECTIOUS DISEASE Company’s descriptionProvided as part of a clinical research engagement. | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $584,246 in research payments for these studies, mostly to the institutions running them.
- A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US)
Theratechnologies Inc. - A phase 2B multicenter, randomized, open-label study comparing the eff
Viiv Healthcare Company - A phase iiib, randomized, multicenter, parallel-group, non-inferiority
Viiv Healthcare Company - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DE…
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.